What is the confirmed 2025 market size and projected 2035 value for the veterinary diagnostics market?
The market was valued at USD 3,784.8 million in 2025 and is forecast to reach USD 7,757.1 million by 2035 at an 8.3% CAGR. POC in-clinic diagnostics are dominant by test volume. Reference laboratory testing is dominant by revenue per test. Molecular diagnostics (PCR, NGS, liquid biopsy) are the fastest-growing technology category. Companion animals are the dominant species segment. North America holds the largest share; Asia-Pacific is the fastest-growing region from in-clinic POC platform adoption at a large developing companion animal practice base.

How does corporate companion animal hospital chain multi-test protocol standardisation drive above-baseline diagnostic test volume?
Corporate companion animal hospital chains — Mars Veterinary Health (Banfield, VCA, BluePearl), National Veterinary Associates, Pathway Vet Alliance — mandate standardised diagnostic protocols: pre-anaesthetic bloodwork (CBC + chemistry) for every surgical patient, senior wellness chemistry panels at every annual visit for dogs above age seven, and in-clinic culture screening before anti-infective prescribing. These protocol mandates increase the average number of in-clinic tests per patient visit above the historical single-test ordering pattern of independent practices, creating above-patient-volume test demand growth that compounds with patient volume growth.

How does companion animal oncology screening represent the most commercially significant new diagnostic category in years?
Companion animal liquid biopsy cancer screening platforms — detecting circulating tumour DNA, cancer-associated proteins, or cancer-specific biomarkers in blood — are creating oncology screening as a new annual wellness visit diagnostic category for companion animals above age seven. Each confirmed positive result generates reference laboratory histopathology, cytology, and flow cytometry confirmation testing, specialist oncology referral, CT staging imaging, and treatment initiation — creating a diagnostic cascade worth USD 3,000–10,000 per confirmed oncology patient. The cancer screening platform creates new recurring per-visit test volume from the large over-seven companion animal patient population.

What drives molecular diagnostics (PCR, NGS) as the fastest-growing veterinary diagnostics technology?
PCR-based pathogen identification — providing same-day bacterial, viral, and parasitic pathogen detection with resistance gene profiling — is replacing culture-and-sensitivity microbiology that requires 48–72 hours for pathogen growth. Next-generation sequencing (NGS) for companion animal cancer mutational profiling and antimicrobial resistance surveillance is growing from oncology specialist and academic veterinary demand. Molecular diagnostic adoption is sustained by the superior speed, sensitivity, and specificity above conventional culture-based methods for infectious disease diagnosis and oncology characterisation.

How does the IDEXX Catalyst biochemistry platform create a recurring per-test consumable revenue model?
IDEXX Catalyst — providing in-clinic biochemistry, electrolytes, and immunoassay testing via single-use reagent rotor disc — creates a recurring per-test consumable revenue stream from the installed companion animal practice base. Each Catalyst rotor disc consumed per biochemistry test sustains manufacturer revenue proportional to in-clinic test volume growth above the one-time instrument capital purchase. Corporate companion animal chain pre-anaesthetic protocol mandates and senior wellness panel requirements grow per-practice rotor disc consumption above patient population growth, sustaining Catalyst consumable revenue at above-patient-volume growth rates.

What is driving veterinary diagnostics demand in Asia-Pacific markets?
Asia-Pacific veterinary diagnostics demand is growing from two simultaneous drivers: new in-clinic POC platform adoption as the large Chinese, South Korean, and Japanese companion animal general practice base invests in first-time in-clinic diagnostic capability, and rising reference laboratory test submission rates as companion animal health standards increase and veterinary diagnostic awareness grows. Urban corporate companion animal hospital chains in China and South Korea are leading POC platform adoption, with reference laboratory test volume growing from increasing diagnostic testing intensity per patient visit as veterinary practice standards rise.